Calreticulin as a hydrophilic chimeric molecular adjuvant enhances IgG responses to the spike protein of severe acute respiratory syndrome coronavirus

Microbiology and Immunology

Volumn 56, Issue 8, 2012, Pages 554-561

  Qiu, Xiang ^a   Hong, Chao ^b   Li, Yue ^a   Bao, Wanrong ^b   Gao, Xiao Ming ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Antibody; Calreticulin; Severe acute respiratory syndrome associated coronavirus; Spike protein

Indexed keywords

CALRETICULIN; HYBRID PROTEIN; IMMUNOGLOBULIN G; RECOMBINANT SPIKE 450-650 CALRETICULIN FUSION PROTEIN; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS SPIKE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HELPER CELL; HUMORAL IMMUNITY; HYDROPHILICITY; IMMUNIZATION; IMMUNOGENICITY; MACROPHAGE; MOUSE; NONHUMAN; PLASMID; PROKARYOTIC CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CALRETICULIN; FEMALE; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; RECOMBINANT FUSION PROTEINS; SARS VIRUS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

CORONAVIRUS; MURINAE; MUS; MUS MUSCULUS; PROKARYOTA; SARS CORONAVIRUS;

EID: 84864340584     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2012.00467.x     Document Type: Article

References (27)

1. Rota PA., Oberste MS., Monroe SS., Nix WA., Campagnoli R., Icenogle JP., Penaranda S., Bankamp B., Maher K., Chen MH., Tong S., Tamin A., Lowe L., Frace M., DeRisi JL., Chen Q., Wang D., Erdman DD., Peret TC., Burns C., Ksiazek TG., Rollin PE., Sanchez A., Lick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Gunther S., Osterhaus AD., Drosten C., Pallansch MA., Anderson LJ., Bellini WJ. (2003) Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300: 1394-9.
2. Marra MA., Jones SJ., Astell CR., Holt RA., BrooksWilson A., Butterfield YS., Khattra J., Asano JK., Barber SA., Chan SY., Cloutier A., Coughlin SM., Freeman D., Girn N., Griffith OL., Leach SR., Mayo M., McDonald H., Montgomery SB., Pandoh PK., Petrescu AS., Robertson AG., Schein JE., Siddiqui A., Smailus DE., Stott JM., Yang GS., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K., Booth TF., Bowness D., Czub M., Drebot M., Fernando L., Flick R., Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A., Kabani A., Li Y., Normand S., Stroher U., Tipples GA., Tyler S., Vogrig R., Ward D., Watson B., Brunham RC., Krajden M., Petric M., Skowronski DM., Upton C., Roper RL. (2003) The genome sequence of the SARS-associated coronavirus. Science 300: 1399-404.
3. Zhao JC., Wang W., Jia RJ., Yuan ZH., Zhao ZD., Xu XJ., Lv P., Zhang Y., Gao XM. (2007) A study on antigenicity and receptor-binding ability of fragment 450-650 of the spike protein of SARS-corona virus. Virology 359: 362-70.
4. Wong SK., Li W., Moore MJ., Choe H., Farzan M. (2004) A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 279: 3197-201.
5. Babcock GJ., Esshaki DJ., Thomas WD Jr., Ambrosino DM. (2004) Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol 78: 4552-60.
6. He Y., Lu H., Siddiqui P., Zhou Y., Jiang S. (2005) Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation- dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 174: 4908-15.
7. Zhou T., Wag H., Luo D., Rowe T., Wang Z., Hogan RJ., Qiu SH., Bunzel RJ., Huang G.Q., Mishra V., Voss TG., Kimberly R., Luo M. (2004) An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies. J Virol 78: 7217-26.
8. Zhao JC., Wang W., Wang WL., Zhao ZD., Zhang Y., Lv P., Ren FR., Gao XM. (2007) Comparison of IgG responses against the spike and nucleocapsid proteins of SARS-coronavirus in patients with severe acute respiratory syndrome. Clin Vaccine Virology. 14: 839-46.
9. Zhao JC., Wang W., Wang GF., Yuan ZH., Jia RJ., Xu X., Ren FR., Zhao ZD., Gao XM. (2005) Development and evaluation of n enzyme-linked immunosorbent assay for detection of antibodies against the spike protein of SARS-coronavirus. J Clin Virol 33: 12-8.
10. Zhao JC., Zhao ZD., Wang W., Gao XM. (2005) Prokaryotic expression, refolding, and purification of fragment 450-650 of the spike protein of SARS-coronavirus. Protein Expr Purif 39: 169-74.
11. Michalak M., Groenendyk J., Szabo E., Gold LI., Opas M. (2009) Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J 417: 651-66.
12. Hong C., Qiu X., Zhong ZY., Huang QR., Li Y., Zhang Y., Lv P., Gao XM. (2010) Functional analysis of a recombinant calreticulin fragment 39-272: Implications for immunobiological activities of calreticulin in health and disease. J Immunol 185: 4561-9.
13. Cheng WF., Hung CF., Chai CY., Hsu KF., He L., Ling M., Wu TC. (2001) Tumor-specific immunity and anti-angiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108: 669-78.
14. Cheng WF., Hung CF., Chen CA., Lee CN., Su YN., Chai CY., Boya DA., Hsieh CY., Wu TC. (2005) Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and anti-angiogenesis. Vaccine 23: 3864-74.
15. Park YS., Lee JH., Hung CF., Wu TC., Kim TW. (2008) Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect Immun 76: 1952-9.
16. Kim TW., Lee JH., Hung CF., Peng S., Roden R., Wang MC., Viscidi R., Tsai YC., He LM., Chen PJ., Boyd DA., Wu TC. (2004) Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J Virol 78: 4638-45.
17. Koch BF., Stanzl U., Jennewein P., Janke K., Heufler C., Kimpgen E., Romani N., Schuler G. (1996) High level IL-12 production by murine dendritic cells: upregulation via MHCclass II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med 184(2): 741-6.
18. Binder RJ., Strivastava P. (2007) HSP-APC interactions: initiation of immune responses. In: A.A. Asea, A. De Maio (eds.)Heat shock proteins: potent mediators of inflammation and immunity. New York : Springer, pp. 131-45.
19. Duus K., Pagh RT., Holmskov U., Hojrup P., Skov S., Houen G. (2007) Interaction of calreticulin with CD40 ligan, TRIAL and Fas ligand. Scand J Immunol 66: 501-7.
20. Basu S., Binder RJ., Ramalingam T., Srivastava PK. (2001) CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 4: 303-13.
21. Berwin B., Hart JP., Rice S., Gass C., Pizzo SV., Post SR., Nicchitta CV. (2003) Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. EMBO J 22: 6127-36.
22. *2705-restricted NP383-391 epitope affects the human influenza A virus-specific cytotoxic T-lymphocyte response in vitro. J Virol 78: 5216-22.
23. Rimmelzwaan G.F., Boon AC., Voeten JT., Berkhoff EG, Fouchier RA., Osterhaus AD. (2004) Sequence variation in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. Virus Res 103: 97-100.
24. Wahl A., McCoy W., Schafer F., Bardet W., Buchli R., Fremont DH., Hildebrand WH. (2009) T-cell tolerance for variability in an HLA class I-presented influenza A virus epitope. J Virol 83: 9206-14.
25. van den Berg RH., Siegert CE., Faber-Krol MC., Huizinga TW., van Es LA., Daha MR. (1998) Anti-C1q receptor/calreticulin autoantibodies in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 111: 359-64.
26. Boehm J., Orth T, Van Nguyen P., Soling HD. (1994) Systemic lupus erythematosus is associated with increased auto-antibody titers against calreticulin and grp94, but calreticulin is not the Ro/SS-A antigen. Eur J Clin Invest 24: 248-57.
27. Zhao JC., Huang QR., Wang W., Zhang Y., Lv P., Gao XM. (2007) Identification and characterization of helper T cell epitopes in the nucleocapsid protein of SARS-CoV. J Virology 81: 6079-88.